Source: Health Products Regulatory Authority (ZA) Revision Year: 2021 Publisher: Litha Pharma (Pty) Ltd, 106 16, th Road, Midrand 1685
Pharmacological classification: A 18.8 Ovulation controlling agents
NOVYNETTE is a monophasic oral contraceptive containing ethinylestradiol and desogestrel that inhibits ovulation. The combination decreases the plasma gonadotropin levels and suppresses ovulation more consistently than either component alone. The viscosity of the cervical mucosa is increased, hindering penetration of the sperm.
Orally administered ethinylestradiol is rapidly and well absorbed from the gastrointestinal tract. As there is some initial conjugation in the gut wall, the systemic bioavailability is only about 40%. Ethinylestradiol is highly protein bound, mainly to albumin. It is metabolised in the liver, and excreted in the urine and faeces. Metabolites undergo enterohepatic recycling.
After oral doses, desogestrel undergoes oxidative transformation to its active metabolite 3-keto-desogestrel in the intestinal mucosa and liver. In the blood, approximately 32% of 3-keto-desogestrel is bound to sex hormone binding globulin, and 66 % to albumin.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
